Want to see XTNT full AI Analyst Report?
XTNT Stock Chart & Stats
$0.33
$0.01(2.61%)
At close: 4:00 PM EDT
$0.33
$0.01(2.61%)
Day’s Range― - ―
52-Week Range$0.27 - $0.95
Previous Close$0.44
Volume19.38K
Average Volume (3M)3.39M
Market Cap
$48.25M
Enterprise Value$74.84
Total Cash (Recent Filing)$9.87M
Total Debt (Recent Filing)$26.01M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Nov 06, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding140,287,960
10 Day Avg. Volume9,646,212
30 Day Avg. Volume3,392,974
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)2.15
Price to Sales (P/S)0.82
P/FCF Ratio10.76
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.03Price Target Upside213.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.03
Revenue Forecast (FY)$100.27M
Bulls Say, Bears Say
Bulls Say
Solid Gross Margin EconomicsFairly consistent gross margins indicate that Xtant’s spine implants and biologics retain attractive underlying product economics. This provides a foundation for improved operating leverage if revenue stabilizes, although current volume and mix pressure must ease before those economics translate into durable earnings.
Improved Balance Sheet LeverageLower leverage and a positive equity base give Xtant a stronger financial cushion than in prior periods. This can support continued investment in products and commercial execution while reducing balance-sheet strain, provided the company avoids a prolonged return to operating and net losses.
Expanded Commercial PlatformThe Dilon integration materially expands sales coverage, institutional relationships, and cross-selling capacity across Xtant’s biologics portfolio. HEMOBLAST and the larger commercial team could broaden product adoption over the next several quarters, creating a more scalable route to revenue growth.
Bears Say
Revenue Decline And Lower GuidanceThe sharp quarterly revenue decline and reduced full-year guide show that Xtant’s growth trajectory is currently unstable. Asset changes, license cessation, and biologics weakness are reducing near-term scale, making it harder to absorb fixed costs and establish reliable revenue momentum.
Margin And Profitability DeteriorationMargin compression alongside a swing to negative adjusted EBITDA demonstrates that weaker revenue is affecting operating performance, not merely reported growth. Lower production efficiency and inventory charges may pressure earnings durability until product mix and operating execution improve.
Tighter Liquidity And Weak Cash GenerationThe decline in cash and reduced revolver availability materially limit Xtant’s financial flexibility while profitability and free cash flow remain weak. Tighter liquidity could constrain investment in commercial expansion and leaves less capacity to absorb continued biologics or margin setbacks.
XTNT FAQ
What was Xtant Medical Holdings’s price range in the past 12 months?
Xtant Medical Holdings lowest stock price was $0.27 and its highest was $0.95 in the past 12 months.
What is Xtant Medical Holdings’s market cap?
Xtant Medical Holdings’s market cap is $48.25M.
When is Xtant Medical Holdings’s upcoming earnings report date?
Xtant Medical Holdings’s upcoming earnings report date is Nov 06, 2026 which is in 54 days.
How were Xtant Medical Holdings’s earnings last quarter?
Xtant Medical Holdings released its earnings results on Aug 11, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.02 by -$0.05.
Is Xtant Medical Holdings overvalued?
According to Wall Street analysts Xtant Medical Holdings’s price is currently Undervalued.
Does Xtant Medical Holdings pay dividends?
Xtant Medical Holdings does not currently pay dividends.
What is Xtant Medical Holdings’s EPS estimate?
Xtant Medical Holdings’s EPS estimate is -0.03.
How many shares outstanding does Xtant Medical Holdings have?
Xtant Medical Holdings has 140,287,960 shares outstanding.
What happened to Xtant Medical Holdings’s price movement after its last earnings report?
Xtant Medical Holdings reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.02. Following the earnings report the stock price went down -28.251%.
Which hedge fund is a major shareholder of Xtant Medical Holdings?
Currently, no hedge funds are holding shares in XTNT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xtant Medical Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1.03 (213.13% Upside)
$1.03 (213.13% Upside)
Blogger Sentiment
Bullish
XTNT Sentiment 100%
Sector Average 62%
Sector Average 62%
Crowd Wisdom
Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-23.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Xtant Medical Holdings
Xtant Medical Holdings, Inc., a company based in Belgrade, Montana, specializes in the development, production, and distribution of advanced regenerative medicine products and medical devices. The firm primarily serves orthopedic and neurological surgeons both within the United States and globally. Its comprehensive product portfolio is categorized into several key areas: 1. Biomaterial Offerings: This category includes products like OsteoSponge, which provides a natural structural support for cellular growth and introduces vital bone-forming proteins to aid the healing process. OsteoSponge SC is specifically designed to repair bone defects in the subchondral area of joints. Other items are OsteoSelect DBM Putty, fostering osteoinductive bone regeneration, and OsteoSelect PLUS DBM Putty, which functions as a bone void filler and graft substitute for procedures involving the pelvis, extremities, and posterolateral spine. Additionally, the line features OsteoFactor, containing diverse proteins and peptides that facilitate bone formation and remodeling, along with OsteoWrap and OsteoVive Plus, a cellular bone matrix enriched with growth factors. 2. Allograft Technologies: Under the 3Demin brand, Xtant Medical provides a range of allografts (human bone grafts) engineered to maximize both osteoconductivity and osteoinductive capabilities. This includes specialized sports allografts used for repairing anterior and posterior cruciate ligaments, ACL reconstruction, and meniscal repairs. They also offer milled spinal allografts, where cortical bone is precisely shaped to specific dimensions, as well as traditional allografts applicable across numerous medical disciplines such such as orthopedics, neurology, podiatry, oral/maxillofacial surgery, genitourinary, and plastic/reconstructive surgery. 3. Spinal Fixation and Fusion Systems: The company furnishes a variety of sophisticated spinal devices. These include the Certex spinal fixation system, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, the Xpress minimally invasive pedicle screw system, and Fortex Pedicle screw systems. Further systems encompass Calix, for use in cervical and thoracolumbar regions, the Axle-X interspinous fusion system, Irix-C for cervical integrated fusion, and the Irix-A Lumbar integrated fusion system. The company underwent a name change in July 2015, transitioning from its former identity as Bacterin International Holdings, Inc. to Xtant Medical Holdings, Inc.
XTNT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presents meaningful strategic and commercial progress — notably the Dilon distribution agreement, integration of 17 new sales reps, product launches (Trivium Shaped) and expanded TAM — which position Xtant for future growth. However, the quarter showed significant near-term financial deterioration: sharp year-over-year revenue decline, gross margin compression, a swing to a net loss and negative adjusted EBITDA, reduced cash balances and a modestly reduced full-year revenue guide. Many negative results are tied to one-time transitions (asset sales, license cessation, Dilon integration) and strategic investments, but the immediate financial metrics are weak while visibility into near-term cash/earnings recovery remains uncertain.View all XTNT earnings summariesXTNT Stock 12 Month Forecast
Average Price Target
$1.03
▲(213.13% Upside)
Technical Analysis
Integra Lifesciences
―
Orthofix Medical
―
Stryker
―
Zimmer Biomet Holdings
―
Bioventus
―
Ownership Overview
12.05% Insiders
1.84% Mutual Funds
53.90% Other Institutional Investors
30.73% Public Companies and
Individual Investors








